Načítá se...

New Strategies in Overcoming Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

The management of non-small cell lung cancer (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in EGFR are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKIs). In these patients, acquired resistance to EGFR-TKI develops after a median of 10-14 mon...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Oxnard, Geoffrey R., Arcila, Maria E., Chmielecki, Juliann, Ladanyi, Marc, Miller, Vincent A., Pao, William
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3166976/
https://ncbi.nlm.nih.gov/pubmed/21775534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2571
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!